Company intelligence / Profile preview

Zoetis Inc.

Parsippany, New Jersey, United Stateszoetis.com ↗

Ownership: Public · ZTS
Employees: ~13800
Development stage: Commercial

Overview

Zoetis has a diverse portfolio of commercial products across multiple therapeutic areas for both companion animals and livestock. Recent approvals include Librela and Solensia for osteoarthritis pain in dogs and cats, and a chewable version of Apoquel for allergic skin conditions in dogs.

Therapeutic areas: DermatologyInfectious DiseasesRheumatology
Modalities: Vaccinesmedicinesdiagnosticsparasiticidesanti-infectivesdermatology productspain and sedation products
Industry: Veterinary

Drug pipeline

4 assets

Librela

Commercial

Indications: Canine osteoarthritis

3 more assets in the full pipeline.

Request access →

Partnerships

Ceres Nanosciences

Financials

Market cap: $30.7B
Total revenue: $2.5B
Enterprise value: $38.3B

Beyond the preview

Go deeper on Zoetis Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zoetis Inc..

Explore the full profile